Xenon temporarily pauses new patient enrollment in depression trials
Xenon Pharmaceuticals said it has temporarily paused enrolling new patients in clinical studies testing its experimental drug for major and bipolar depression after reports of mental and nervous system-related side effects.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.